62nd ASH Annual Meeting and Exposition: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Poster III

Oral and Poster Abstracts
Poster

Adult, AML, Biological, Coronaviruses, Leukemia, multiple myeloma, SARS-CoV-2/COVID-19, therapy sequence, CML, Diseases, Lymphoma (any), Non-Biological, Bone Marrow Failure, Combinations, Elderly, Therapies, chemotherapy, Non-Hodgkin Lymphoma, Biological Processes, DLBCL, MPN, Polycythemia vera, Technology and Procedures, immunotherapy, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Clinically relevant, genomics, Myeloid Malignancies, Quality Improvement , TKI, molecular testing, NGS

3437

Indirect Treatment Comparison of CC-486 Versus Azacitidine (AZA) As Maintenance Therapy for Acute Myeloid Leukemia (AML)

Ashley Tabah¹^*, David Huggar¹^*, Si-Tien Wang²^*, Scott J. Johnson²^*, Ronda Copher, PhD¹^*, Thomas O'Connell²^* and Thomas W. Leblanc³

¹Bristol Myers Squibb, Princeton, NJ
²Medicus Economics, Boston, MA
³Duke Cancer Institute, Durham, NC

3438

Meletios A. Dimopoulos, MD¹, Frank Campana, MD²^*, Denise Bury, MPH, PhD²^*, Sophie Guillonneau³^*, Cheng Zheng²^*, Peggy Lin, PhD²^*, Paul G. Richardson, MD⁴ and Michel Delforge, MD PhD⁵

¹Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
²Sanofi Genzyme, Cambridge, MA
³Sanofi Genzyme, Chilly-Mazarin, France
⁴Dana-Farber Cancer Institute, Boston, MA
⁵Department of Hematology, University Hospital Leuven, Leuven, Belgium

3439

Criteria for Ordering Myeloid Neoplasm Next-Generation Sequencing to Optimize Personalized Patient Care and Cost

Savanah D. Gisriel, MD, MPH¹^*, Henry M. Rinder, MD² and Alexa J. Siddon, MD³

¹Department of Pathology, Yale School of Medicine, Hamden, CT
²Departments of Laboratory Medicine & Medicine (Hematology), Yale School of Medicine, New Haven, CT
³Departments of Laboratory Medicine and Pathology, Yale School of Medicine, New Haven, CT

3440

Feasibility of a Decision Support Software to Aid in the Interpretation of Somatic Mutations Detected in Hematologic Malignancies

Stephanie J. Yaung, PhD¹^*, Adeline Pek, MS¹^*, Lili Niu, PhD²^*, Jian Li, PhD²^*, John F. Palma, PhD¹^* and Maximilian Schmid, MD¹^*

¹Roche Sequencing Solutions, Inc., Pleasanton, CA
²Roche Sequencing Solutions, Inc., Belmont, CA

3441

Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic

Kimberly C Jenkins, MSNM¹^*, Emily C Zabor, DrPH²^*, Lindsey A. R. Mooney, BS¹^*, Aaron T. Gerds, MD, MS³, Kerry O'Hop, BS⁴^*, Makenzie Guy, BA⁴^*, Megan Kilbane, MBA¹^*, Nathan A Pennell, MD, PhD⁴^* and Mikkael A. Sekeres, MD, MS⁵

¹Hematology and Medical Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
²Quantitative Health Sciences, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
³Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁴Lung Program, Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁵Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

3442

Real-World Investigation of Spleen, Symptom, and Hematologic Response in Patients with Myelofibrosis Treated with First-Line Ruxolitinib

Jonathan K. Kish, PhD, MPH¹^*, Arianna Kee²^*, Pranav Abraham²^*, Ronda Copher, PhD²^*, Talia Miller¹^* and Aaron T. Gerds, MD, MS³

¹Cardinal Health, Dublin, OH
²Bristol Myers Squibb, Princeton, NJ
³Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

3443

Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States

Rory M. Shallis, MD¹, Rong Wang, PhD²^*, Jan Philipp Bewersdorf, MD³^*, Amer M. Zeidan, MBBS, MHS⁴, Scott F. Huntington, MD, MPH⁵, Amy J Davidoff, PhD, MS⁶^*, Xiaomei Ma, PhD⁷^* and Nikolai A. Podoltsev, MD, PhD⁸

¹Yale Cancer Center, West Haven, CT
²Yale University School of Public Health, New Haven, CT
³Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT
⁴Yale University School of Medicine and Yale Cancer Center, New Haven, CT
⁵Hematology, Yale University School of Medicine, New Haven, CT
⁶Department of Health Policy and Management, Yale University School of Public Health, New Haven, CT
⁷Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, New Haven, CT
⁸Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, Madison, CT

3444

Economic Burden of Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Study Using the SEER-Medicare Database

Ashley Tabah¹^*, David Huggar¹^*, Krystal Huey¹^*, Ronda Copher, PhD¹^*, Zheng-Yi Zhou²^*, Miriam L. Zichlin³^*, Sarah H. Koenigsberg²^* and Andrew M. Brunner⁴^*

¹Bristol Myers Squibb, Princeton, NJ
²Analysis Group Inc., Boston, MA
³Analysis Group, Inc., Boston, MA
⁴Massachusetts General Hospital, Boston, MA

3445

Outcomes of Patients with Hematologic Malignancies Who Received Inpatient Palliative Care Consultation

Anthony Vito Pasquarella, MD¹, Angela Ramdhanny, MD²^*, Mina Gendy, DO¹^*, Priya Pinto, MD³^*, Shahidul Islam, DrPH, MPH, PStat⁴^* and Marc Braunstein, MD, PhD⁵

¹Division of Hematology/Oncology, NYU Long Island School of Medicine, Mineola, NY
²Department of Internal Medicine, NYU Winthrop Hospital, Mineola, NY
³Division of Palliative Care, NYU Long Island School of Medicine, Mineola, NY
⁴Department of Biostatistics, NYU Long Island School of Medicine, Mineola, NY
⁵Division of Oncology-Hematology, NYU Long Island School of Medicine, NYU Winthrop Hospital, NYU Langone Health, Great Neck, NY

3446

Identifying Myeloid Mutations By NGS in Patients with Unexplained Erythrocytosis

Eri Kawata, MD, PhD^1,2,3, Anargyros Xenocostas, MD, FRCPC^4,5, Cyrus C. Hsia, MD, BSc, FRCPC^4,5,6, Alejandro Lazo-Langner, MD, MSc^4,5, Michael Levy, PhD⁷^*, Stephanie Santos⁷^*, Hanxin Lin, PhD^6,7^*, Chris Howlett^6,7^*, Bekim Sadikovic, PhD, DABMGG, FACMG^6,7^* and Ian Chin-Yee, MD, FRCPC^4,5,6

¹Division of Hematology, Department of Medicine, London Health Sciences Centre, Kyoto-Shi, KYO, Japan
²Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
³Department of Hematology, Matsushita Memorial Hospital, Moriguchi, Japan
⁴Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
⁵Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON, Canada
⁶Department of Pathology & Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
⁷Molecular Genetics Laboratory, London Health Sciences Centre, London, ON, Canada

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH